NCT00771251 - A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA) | Biotech Hunter

Enrollment

311

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CNTO 148

50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.

DRUG

Placebo

Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.

Trial Locations (67)

Unknown

Asahikawa

Ayauta

Azumino

Chiba

Fuchū

Fukui

Fukuoka

Fukushima

Gifu

Goshogawara

Hachiōji

Hamamatsu

Higashi-Hiroshima

Hiki

Hiroshima

Hitachi

Hitachi-Naka

Iruma

Izumisano

Izumo

Kamakura

Katō

Kawachi-Nagano

Kawagoe

Kawasaki

Kita-Gun

Kitakyushu

Kitamoto

Kobe

Kumamoto

Kyoto

Matsue

Matsumoto

Matsuyama

Nagano

Nagoya

Narashino

Niigata

Nishinomiya

Ohta-Ku

Osaka

Ōita

Ōsaka-sayama

Ōsaki

Sagamihara

Saitama

Sapporo

Sasebo

Sendai

Shimotsuga

Shimotsuke

Shinjuku-Ku

Shizuoka

Suita

Tokushima

Tokyo

Tomigusuku

Toshima-Ku

Toyama

Toyoake

Toyohashi

Tsu

Tsukuba

Tsukubo

Ube

Yokohama

Yufu